SEC Form 4 · accession 0001609351-18-000038
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Furey
Officer — Chief Operating Officer
Period of report
Apr 20, 2018
Accepted (ET)
Apr 24, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 20, 2018 | M | 6,723 | $49.74 | A | 6,723 | D | |
| Common Stock | Apr 20, 2018 | S | 6,723 | $82.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $49.74 | Apr 20, 2018 | M | 6,723 | D | — | Nov 30, 2026 | Common Stock | 6,723 | 120,000 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.
- F225% vests December 1, 2017 and the remainder vests in equal quarterly installments over the following three years following December 1, 2017.